726192-98-9

Upstream product

• 75-16-1 methylmagnesium bromide 
• 74879-18-8 (S)-2-methylpiperazine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 726192-95-6 (S)-4-[(S)-1-(4-Methanesulfonyl-phenyl)-ethyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 726192-09-2 Methanesulfonic acid (R)-1-(4-methanesulfonyl-phenyl)-ethyl ester 
• 147081-29-6 (S)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 726192-01-4 (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol 
• 10297-73-1 4-(methanesulfonyl)acetophenone 

Relevant academic research and scientific papers

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten

Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm